Floatz logo

Fingolimod

Cognitive Disorder

Novartis PharmaceuticalsSmall moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
89/ 100

Competitive context

132 Active assets in the Cognitive Disorder cohort.

Asset / SponsorPhaseRating
Nicotine
University of Southern California
Phase 2BBB
Oxybutynin
University of Alberta
Phase 4BBB
Levodopa
Vanderbilt University Medical Center
Phase 4BB
Rivastigmine
VA Office of Research and Development
Phase 4BB
Metformin
Fudan University
Phase 4BB

View all 50 →

Same molecule, other indications

Fingolimod is also rated in:

relapsing-remitting multiple sclerosisActive
BBB
Indicative · Phase 4
79 / 100
View asset →
multiple sclerosisActive
BB
Indicative · Phase 4
70 / 100
View asset →
cerebral degenerationDormant
BB
Indicative · Phase 4
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →